ALX Oncology Holdings Inc. (ALXO) Q1 FY26 Earnings Call

CD47-high patients showed strong early efficacy, but validation and regulatory progress depend on larger prospective studies.

Q1 FY26 results, source: company transcript and SEC filings
QuarterQ1 FY26
Call date2026-05-08
Length60 minutes
EPS$-0.17
EPS consensus$-0.15
Revenue$1.2M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

All ALXO earnings ยท Back to ALXO overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.